CAR-T cell therapies aimed at BCMA have shown significant effectiveness in treating relapsed or refractory multiple myeloma, and recent translational efforts have extended BCMA-targeted strategies to autoimmune diseases characterized by pathogenic PC activity [37,38]. This evidence concerns the gene TNFRSF17 and plasma cell myeloma.